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1. Introduction 
The steroid hormone receptors, the Androgen Receptor (AR), Estrogen Receptors (ER┙ and 
ER┚), Glucocorticoid Receptor (GR), Mineralocorticoid Receptor and Progesterone Receptor 
(PR), have been crucial targets for drug discovery even before their existence was known or 
understood. The drugs on the market for this sub-class of the nuclear hormone receptors 
constitute a significant pharmacopeia for the treatment of a vast array of conditions and 
ailments. Despite the breadth of drugs targeted toward this family, they remain an 
important target for the pharmaceutical industry. 
Key considerations when designing drugs for any family, beyond the on-target 
pharmaceutical action and safety, is to ensure specificity against related targets, exploration 
of the most appropriate routes of administration and desirable pharmacokinetic (PK) 
profiles. Developing non-steroidal modulators for the steroid receptor family has been a key 
strategy employed to achieve these goals, although there appears to be growing consensus 
that not being steroidal is insufficient to justify new drugs on its own (Hermkens et al, 2006). 
Unlike targeting many families, steroid hormone receptor drug discovery also has to 
balance the need to elicit either agonistic or antagonistic responses depending on the desired 
indication.  
The history of drug discovery for the steroid hormone receptors has tended to follow a 
common path, beginning with the application of purified endogenous hormone and 
followed by the application of the first synthetic analogs with improved PK properties or 
selectivity. For some of the receptors this period was followed by the design of antagonists, 
including non-steroidal structures. More recently, steroid hormone drug discovery has been 
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dominated by the search for ligands characterized by partial agonistic or partial antagonistic 
responses, the so called selective modulators. It is hoped and expected that partial agonists 
and antagonists for the various receptors will provide improved therapeutic profiles. For 
example, selective GR modulators (SGRMs) could provide their anti-inflammatory action 
without the undesirable side-effects, including osteoporosis and diabetes, currently 
associated with oral glucocorticoids (Hudson, Roach, and Higuchi, 2008). Selective ER 
modulators (SERMs) hold the promise of being active on bone but not breast or endometrial 
tissue (Shelly et al, 2008;Silverman, 2010), whereas a desirable profile for a selective AR 
modulator (SARM) would likely have a greater action in bone and muscle compared to the 
prostate (Gao and Dalton, 2007). 
2. Molecular basis for partial agonism 
The shared domain structure of steroid receptors includes a variable N-terminal domain, a 
highly conserved DNA-binding domain and a moderately conserved ligand-binding 
domain (LBD). The LBD domain tends to be the primary target for drug-design. The LBD 
combines a number of functions, including hormone binding, receptor dimerization and 
binding to other co-modulating proteins that play a role in the control of transcription. 
These functions have the ability to influence each other, with ligand-binding, as an example; 
influencing the pattern of co-modulator recruitment. Specifically, gene activation requires 
the recruitment of co-modulating proteins to a region of the surface of the LBD formed by 
helices 3/4, 5 and 12. The position of helix-12, as we will discuss, can be influenced by the 
nature of the ligand bound to the receptor allowing drugs to influence the binding of co-
modulators and consequently gene activation and the resulting biological effects (Bourguet, 
Germain, and Gronemeyer, 2000;Egea, Klaholz, and Moras, 2000;Kumar and Thompson, 
1999;Weatherman, Fletterick, and Scanlan, 1999).  
Understanding the molecular basis for partial agonism is hampered by the difficulty in 
solving the X-ray structures of steroid-receptors in general and specifically complexes 
including partial active ligands (Nettles et al, 2008). Full agonists stabilize the receptor, and 
specifically helix-12, in a conformation suited to binding co-activating proteins and full 
antagonists stabilize the receptor in a conformation suited to binding co-repressing proteins. 
The apparent reason for the difficulty in co-crystallizing partial agonists is that they do not 
fully stabilize the receptor in either conformation, adopting some degree of equilibrium 
between the two (Nettles et al, 2008;Raaijmakers, Versteegh, and Uitdehaag, 2009). This 
equilibrium allows partially active compounds to bind unique patterns of co-modulators 
compared to full agonists and antagonists, resulting in their potentially interesting 
biological effects. Unfortunately as a result it also renders them poorly suited to co-
crystallization studies. 
The degree of partial activity (how far from either a full agonist or antagonist response) will 
go some way to determining the profile of co-modulators which will bind. Additionally, the 
ratio of co-activators compared to co-repressors in each cell type will influence the biological 
effect of a partial compound. In cells with a high co-activator concentration we would expect 
partial compounds to show a greater degree of agonistic activity compared to the same 
ligand in a cell with a high co-repressor concentration. The limitless combination of ligand 
partiality and co-modulator distribution appears to be a major contributor to the tissue 
selective responses of partial compounds. 
www.intechopen.com
 
Drug Design Approaches to Manipulate the Agonist-Antagonist Equilibrium in Steroid Receptors 
 
223 
3. Mechanisms for ligand-induced partial agonist design 
In the absence of a complete record of X-ray structures of steroid receptors bound to 
agonists, antagonists and partially active compounds, we have to fill in the knowledge gaps 
with mutation studies and ligand-based structure-activity relationships (SAR). Even with 
this extra information, our understanding of the mechanisms underpinning the 
repositioning of helix-12 and the resulting spectrum of partial responses remains relatively 
naive, but there do appear to be a small number of approaches available to the drug 
designer who wishes to rationally influence the degree of agonism elicited by their 
compound series. 
1. Sterically impede the agonistic orientation of Helix-12 
2. Disrupt the function of other indirect stabilizing interactions. 
3. Influence the position of Helix-12 by modulating the end of Helix-11 and the loop 
between Helices 11 & 12. 
4. Reduce the stabilizing interactions between the ligand and Helix-12. 
5. Straighten Helix-3, and/or disrupt interactions between Helices 3 & 5. 
Incorporating these approaches into the optimization of steroid receptor ligands allows the 
drug-designer to modulate the degree of agonistic and antagonistic response their 
compounds induce. Pharmacologically it remains difficult to define a priori the precise 
agonistic or antagonistic efficacy (percentage effect or intrinsic activity) required for any 
desired indication, but it is now possible to generate a series of ligands with tuned efficacies 
to cover a broad range and then utilize molecular profiling approaches to select the most 
desirable. 
The five basic approaches for generating partially active compounds have been deduced by 
numerous studies from all members of the steroid receptors and nuclear receptor family in 
total. For the purposes of this review we present a single receptor case study to demonstrate 
each of the five mechanisms, but wish to stress that to a greater and lesser degree all 
mechanisms should be applicable to all steroid receptors. 
3.1 Sterically impede the agonistic orientation of helix-12 
3.1.1 Case study: the progesterone receptor 
Steroidal anti-progestins are typically differentiated structurally from progestins by the 
presence of a bulky attachment at their position 11 (Madauss, Stewart, and Williams, 
2007). Recent publications of the anti-progestin Mifepristone (Raaijmakers, Versteegh, and 
Uitdehaag, 2009) and the SPRM Asoprisnil (Madauss et al, 2007) clearly demonstrate that 
the role of this bulky attachment is to clash with helix-12 and preclude it from adopting its 
required agonistic position. Both studies also demonstrate an important role specifically 
for Met909 in the agonism/antagonism balance. Met909 sits within helix-12 at the C-
terminal end of the ligand binding domain (LBD), and in the classic agonist conformation 
of the receptor, is oriented toward the ligand binding pocket. Met909 is typically the only 
helix-12 residue directly in contact with ligands. The nature of the ligand-Met909 
interactions appears to be a key determinant of the receptors function (Petit-Topin et al, 
2009). Clashes between Met909 and ligands are likely to destabilize helix-12 (Raaijmakers, 
Versteegh, and Uitdehaag, 2009), which results in a reduced agonistic response. It has 
even been suggested that the degree of clash with Met909 might correspond directly to 
the reduction in agonism (Madauss, Stewart, and Williams, 2007), but this has yet to be 
shown categorically. 
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Introducing bulky groups onto PR modulating non-steroidal scaffolds has also been 
demonstrated to result in partial agonists on a number of occasions (Jones et al, 
2005;Kallander et al, 2010;Thompson et al, 2009;Washburn et al, 2009). 
3.1.2 Additional examples 
The existence of a clash between antagonists and helix-12 was first demonstrated for ER by 
studies comparing the X-ray structures of Estradiol to Raloxifene (Brzozowski et al, 1997) 
and Diethylstilbestrol to Tamoxifen (Shiau et al, 1998). Numerous reviews of these two 
studies have been published (Hubbard et al, 2000;Kong, Pike, and Hubbard, 2003;Mueller-
Fahrnow and Egner, 1999;Pike et al, 2000;Pike, Brzozowski, and Hubbard, 2000) as have 
many further studies on the X-ray structures of SERMs, full antagonists and full agonists 
bound to the ERs (Blizzard et al, 2005;Dykstra et al, 2007;Heldring et al, 2007;Kim et al, 
2004;Renaud et al, 2003;Renaud et al, 2005;Tan et al, 2005;Vajdos et al, 2007). 
 
 
Fig. 1. Binding of PR agonist Norethindrone (orange) from X-ray structure compared to PR 
antagonist Mifepristone (green) demonstrating clash between antagonists and Met909 in 
helix-12. 
The same helix-12 clash has also been demonstrated for AR (Cantin et al, 2007) and GR 
(Schoch et al, 2010) in recent X-ray structure determination studies. It was also suggested for 
GR by a mutagenesis study (Hillmann et al, 2002) that showed that mutating Leu753 
(equivalent to Met909 in PR) to a phenylalanine results in a receptor defective in 
transactivation. We can conclude that the reason for this loss of activation is that an increase 
in the size of the residue at this position prevents helix-12 from adopting its agonistic 
conformation due to a clash with the ligand. 
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3.2 Disrupt the function of direct stabilizing interactions 
3.2.1 Case study: the androgen receptor 
The binding of testosterone and dihydrotestosterone to AR demonstrate the existence of 
crucial receptor stabilizing interactions mediated by agonistic ligands. As we will discuss 
later, the loop between helix-11 and helix-12 is a key region for mediating partial agonism. 
As shown in figure 2, AR is stabilized by a ligand mediated hydrogen-bond network from 
Thr877 in helix-11 to the 17┚-OH group in the endogenous steroidal agonists to Asn705 in 
helix-3 and finally to the backbone of Asp890 in the loop itself (Matias et al, 2000). 
Hydroxyflutamide is the active metabolite of the androgen receptor antagonist flutamide. Its 
antagonism appears to be a result of its inability to complete the entire network of 
stabilizing hydrogen-bonds (Bohl et al, 2005) also shown in figure 2. The result is that 
Thr877 is left buried in a predominately hydrophobic pocket, destabilizing the receptor and 
shifting the agonist-antagonist equilibrium. 
 
 
Fig. 2. Left shows the X-ray structure of DHT bound to AR including full hydrogen-bond 
network. Right shows a model of hydroxyflutamide bound to AR based on the X-ray 
structure of hydroxyflutamide bound to an AR-T877A mutant. 
3.2.2 Additional examples 
The residue equivalent to AR residue Asn705 in MR is Asn770. Extensive X-ray, SAR and 
mutation studies have been conducted on Asn770 which demonstrate clearly the existence 
of a ligand-mediated hydrogen bonding network which is critical for the activation of MR in 
a similar fashion to the one described for AR (Bledsoe et al, 2005;Hellal-Levy et al, 2000).  
Agonistic steroidal ligands for GR and MR are typified by 11┚-hydroxyl groups which 
hydrogen bond to Asn564 in GR and Asn770 in MR respectively. Despite the similarity 
between MR and PR, the endogenous PR agonist progesterone behaves as an antagonist of 
PR. This appears to at least in part be due to a lack of an 11┚-hydroxyl group on 
progesterone. It is interesting how the lack of the hydroxyl group doesn’t disturb the 
agonistic activity of PR but does MR. 
Another important example of disrupting the function of stabilizing interactions can be seen 
in the estrogen receptors. In addition to their role in sterically precluding helix-12, SERM 
side-chains also contain an important basic amine function which is almost ubiquitous 
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amongst this drug class. The role of this nitrogen is to form a salt-bridge to Asp351 in helix-3 
of ER┙ (Asp303 in ER┚). The importance of this salt-bridge is that it requires Asp351 to 
adopt a new conformation and prevents it from undertaking is usual function of stabilizing 
the agonistic position of helix-12 by hydrogen-bonding to backbone residues in the helix. It 
also appears that the exact nature of the interaction between the basic amine and Asp351, 
including angle, distance and perhaps pKa can influence the biological effect of the ligands. 
3.3 Modulate the end of helix-11 & the loop between helices-11 & 12 
3.3.1 Case study: the glucocorticoid receptor 
Due to the difficulty in crystallizing partial agonists in complex with steroid-receptors much 
of the evidence to support these mechanisms has to be inferred from other indirect sources. 
Some of the most valuable evidence comes from mutagenesis studies including those that 
indicate that the loop between helix-11 and helix-12 is a hotspot that is crucial to the 
agonism/antagonism balance in GR. 
Mutation of Ile747, which sits in the middle of the helix-11 to helix-12 loop, to methionine 
results in GR having a reduced transactivation potential without affecting the binding of 
classic glucocorticoids (Vottero et al, 2002). Presumably, the increased size of the residue 
prevents the correct packing of the loop and therefore destabilizes helix-12. 
Tyr735 at the end of helix-11 is a surface residue whose role is poorly understood, but it has 
been shown that various mutations (W735F, W735V and W735S) result in a receptor with 
significant reduction in transactivation activity without affecting ligand binding (Ray et al, 
1999;Stevens et al, 2003). 
Thr739 is the last residue in helix-11 whose mutation to alanine has no effect on the binding 
of triamcinolone acetonide, but does result in a 16-fold reduction in transactivation (Lind et 
al, 2000). 
In addition to these mutation studies, as discussed already, there is also overwhelming 
evidence across the family to support the hypothesis that Asn564 is crucial for the agonistic 
activity of GR and related receptors (Bledsoe et al, 2005;Bledsoe, Stewart, and Pearce, 
2004;Fagart et al, 1998;Hellal-Levy et al, 2000;Necela and Cidlowski, 2003;Rafestin-Oblin et 
al, 2002). The role of Asn564 (Asn705 in AR, Asn770 in MR) was previously discussed. 
Tyr735, Thr739 and Ile747, as shown in Fig 3, are all located at the end of helix-11 or in the 
following loop. Asn564 has an important role in stabilizing the loop. The studies associated 
with each of these residues indicate how sensitive this region to influencing the agonism/ 
antagonism balance and therefore the potential to modify its function by ligand design. 
The helix-11 to helix-12 loop in steroid-receptors is well suited to drug-design intervention 
as it forms around the 17┚ group of steroids and is therefore likely to be in close proximity 
to most ligands. 
Bledsoe and colleagues recognized the importance of this region when solving the first GR-
Dexamethasone structure (Bledsoe et al, 2002;Bledsoe, Stewart, and Pearce,2004) as did the 
group of Kauppi when solving GR complexed with Dexamethasone and RU486, including 
noting the flexibility of this loop (Kauppi et al, 2003). 
3.3.2 Additional examples 
The importance of the loop region between helix-11 and helix-12 has also been 
demonstrated by X-ray structure studies for ER┙ (Pike et al, 1999;Shiau et al, 1998), and 
mutagenesis studies on MR also support the conclusion that this region of the steroid-
receptors is crucial for the agonism/antagonism balance (Fagart et al, 2005). 
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Fig. 3. The loop between helix-11 and helix-12 illustrating key residues believed to influence 
GR function 
3.4 Reduce the stabilizing interactions between the ligand and helix-12 
3.4.1 Case study: the estrogen receptors alpha & beta 
Methods for antagonizing or reducing the agonism of steroid receptors that do not involve 
direct steric clashes with the receptor are often referred to as “passive antagonism”. This 
term was coined by the group of Geoffrey Greene to explain their observations when 
studying the binding of tetrahydrochyrsene (THC) and its interactions with ER┙ and ER┚ 
(Shiau et al, 2002). 
THC is an ER┙ agonist and an ER┚ antagonist. The group of Greene was able to conclude, 
after generating X-ray structures of both complexes that THC stabilizes ER┙ in its agonist 
conformation but ER┚ is in an antagonist conformation. This difference on its own is of 
significant interest, but the study also demonstrated that the reason for ER┚ not adopting an 
agonist conformation was due to missing stabilizing interactions between the receptor and 
the ligand. They observe that in ER┚ residues Leu476 and Met479 are not positioned 
correctly by the ligand to form interactions with relevant residues in helix-12 to stabilize its 
agonist conformation. The result is a failure of THC to stabilize the agonist conformation of 
helix-12 and therefore a shift in the agonist-antagonist equilibrium. The fact that THC has 
such differing effects on two such similar receptors illustrates the challenge when following 
this or any of the five described approaches in drug-design. 
3.5 Straighten helix-3, and/or disrupt interactions between helices-3 & 5 
3.5.1 Case study: the mineralocorticoid receptor 
It is generally accepted that steroid-receptor activation is facilitated by interactions between 
helix-3 and helix-5. The correct positioning of the basic component of the charge clamp 
(Lys579 in GR and Lys785 in MR) and the formation of the hydrophobic pocket in which co-
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activators bind is dependent on a bend forming in the middle of helix-3. That bend in helix-3 
is induced by a ligand mediated hydrogen bond to helix-5 via the 3-keto group of steroidal 
ligands. It was initially believed that the importance of the classic interactions between the 
3-keto group of steroids and the Glutamine (Glutamate in ER┙ and ER┚) and Arginine 
residues in steroid hormones was purely to ensure potent binding of the steroids, but the 
work of Bledsoe (Bledsoe et al, 2005) and Huyet (Huyet et al, 2007) have demonstrated that 
is also has a role in the agonism-antagonism balance. Huyet et al demonstrated that 
mutation of either Gln776 or Arg817 in MR to alanine results in previously ligand-mediated 
agonistic responses being lost.  
Bledsoe et al have further demonstrated the importance of this bend in helix-3 by 
characterizing the S810L mutation in MR. This mutation has the effect of stabilizing the 
agonist conformation of MR, rendering some antagonistic ligands to have an increased 
agonistic response. Their analysis shows that the role of the S810L mutation is to increase 
the hydrophobic stabilization between helix-3 and helix-5. 
3.5.2 Additional example 
A recent X-ray structure publication from our group suggests that PR antagonism seen in a 
compound series can in part be explained by a loss of these same interactions (Lusher et al, 
2011). 
4. Pictorial summary of five drug design approaches 
 
Fig. 4. Binding of Dexamethasone (DEX) to GR 
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4.1 Binding mode of DEX to GR illustrates each of the five design approaches  
The binding of Dexamethasone to the Glucocorticoid Receptor (GR) is shown to illustrate 
the five major routes for reducing agonist efficacy in steroid receptors via the destabilisation 
of the binding of co-activating proteins. Co-activating proteins bind in a hydrophobic pocket 
on the surface of the ligand-binding domain (LBD) stabilised by a charge-clamp formed by 
residues Lys579 in helix-3 and Glu755 in helix-12. [1] Direct clashes between ligands and 
helix-12 prevent Glu755 from adopting its necessary position and thus prevent the 
formation of the charge clamp. It has been shown for some receptors that clashes with helix-
12 result in the helix adopting a new orientation actually precluding the binding of co-
activators by binding in the required hydrophobic pocket. [2] It is probably therefore not a 
surprise that the positioning of helix-12 can be influenced by the residues that directly 
precede it. The loop before helix-12 influences its position and is clearly a hotspot that can 
influence degree of agonism by modifying the ligand. [3] Other interactions also help 
stabilise helix-12 in its agonist position. For example, in GR, there is a hydrogen-bond 
network from the ligand to Asn564 in helix-3 to Glu748 in the loop before helix-12. 
Disruption of this network, by perhaps removing the hydrogen-bonding function in the 
ligand, can influence the stabilisation of helix-12. [4] In a number of nuclear receptors Helix-
12 also makes direct hydrophobic interactions to the ligand. Loss of these interactions, by 
changing the properties of the ligand, can decrease the stabilisation of helix-12 and 
therefore alter the agonistic capability of the complex. [5] Finally, the first four approaches 
are directly or indirectly related to ensuring Glu755, as half of the charge-clamp, is 
correctly positioned. The second residue in the charge-clamp, Lys579, should not be 
overlooked. Lys579 is part of helix-3 which itself bends midway along its length. This 
bend is crucial for ensuring that Lys579 is in the correct position to form the charge-
clamp. The bend in helix-3 is partly as a result of its interaction with helix-5. For GR this is 
largely mediated by a hydrogen-bond network between Gln570 in helix-3, the ligand and 
Arg611 in helix-5. Disrupting this network by modifying the ligand may influence the 
distortion in helix-3 and therefore the correct formation of the charge-clamp and therefore 
co-activator binding. 
5. Other structure-based design considerations 
In addition to exploring the development of partial agonists, structure-based approaches 
continue to play an important role in the identification of new ligands via virtual screening 
approaches and other compound optimization tasks. An important lesson in this regard has 
been our change in understanding the dynamic nature of the steroid-receptor binding 
pocket. We have seen examples of extensive induced fits for amongst others the 
glucocorticoid receptor which is able to bind ligands beyond the conventional confines of its 
binding pocket whilst remaining in an agonistic conformation (Biggadike et al, 
2009;Madauss et al, 2008;Suino-Powell et al, 2008). The pocket, behind the crucial helix-3 
and helix-5 binding residues, Gln570 and Arg611, is normally water filled. It has already 
been demonstrated to be a viable ligand-binding region with the potential to improve ligand 
potency. An interesting note regarding the exploration of the pocket is that GSK report 
difficulty in combining the use of this pocket with the maintenance of partial agonism 
(Biggadike et al, 2009). PR has been shown to adapt to steroids baring bulky 17┙ groups 
(Madauss et al, 2004) and Trp741 in AR adapts to different ligands, adopting a new position 
to open an additional channel in the receptor (Bohl et al, 2005). 
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6. Conclusion 
As we look to the future of rational and structure-based drug design for the steroid receptors 
there remain key areas and questions that will dominate research in the short to medium term: 
1. Is each of the five described methods for generating partial compounds equally 
applicable for each of the receptors? It is generally considered true that ER┚ is easier to 
antagonize than ER┙. This is most likely due to the agonist conformation of ER┚ being 
less intrinsically stable than ER┙ and therefore ensuring that ER┚ is more sensitive than 
ER┙ in this respect (Pike et al, 1999). 
2. Does the choice of the mechanism for instilling partiality affect the eventual biological 
activity? Does a compound with a 40% reduction in agonistic activity due to a clash 
with helix-12 have the same biological effect as a compound with a 40% reduction in 
agonism due to the loss of other stabilizing interactions? 
3. As described earlier, partial agonists and antagonists are often poor candidates for co-
crystallization Recently we have seen the first publications describing methods to 
circumvent this problem, either by introducing stabilizing mutations into the receptor 
(Bohl et al, 2007;Fagart et al, 2005;Nettles et al, 2008;Sack et al, 2001) or by generating 
stable crystals of the receptor using a receptor stabilizing ligand and then exchanging 
this compound with other compounds of interest via soaking (Raaijmakers, Versteegh, 
and Uitdehaag, 2009). Both approaches have the potential to dramatically increase our 
understanding of the biological mechanisms underpinning partial agonism. 
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